Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760461 · ClinicalTrials.gov registry record · Phase 2
Domperidone in Refractory Gastroparesis
A Phase 2 study, sponsored by Yale University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00760461 is a Phase 2 study that was terminated before completion, run by Yale University. The registered enrollment target is 44 participants.
The verdict
NCT00760461, a Phase 2 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.
Interventions
- DRUG Domperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760461
The ClinicalTrials.gov registry entry for NCT00760461 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Domperidone is the first listed.
NCT00760461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00760461 about?
NCT00760461 is a clinical study titled "Domperidone in Refractory Gastroparesis". The primary objective of this study is to prescribe oral domperidone for patients with gastroparesis who have failed or suffered adverse effects from standard medical therapy.
What is the current status of trial NCT00760461?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2008-10. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00760461?
The interventions under investigation include: Domperidone (DRUG).
Who is sponsoring clinical trial NCT00760461?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.